Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Abstract Text:

Hideo Kunitoh,Harubumi Kato,Masahiro Tsuboi,Taro Shibata,Hisao Asamura,Yukito Ichonose,Nobuyuki Katakami,Kanji Nagai,Tetsuya Mitsudomi,Akihide Matsumura,Ken Nakagawa,Hirohito Tada,Nagahiro Saijo, ,Hideo Kunitoh,Harubumi Kato,Masahiro Tsuboi,Taro Shibata,Hisao Asamura,Yukito Ichonose,Nobuyuki Katakami,Kanji Nagai,Tetsuya Mitsudomi,Akihide Matsumura,Ken Nakagawa,Hirohito Tada,Nagahiro Saijo, ,

PURPOSE: To evaluate the safety and efficacy of preoperative chemoradiotherapy followed by surgical resection for superior sulcus tumors (SSTs). PATIENTS AND METHODS: Patients with pathologically documented non-small-cell lung cancer with invasion of the first rib or more superior chest wall were enrolled as eligible; those with distant metastasis, pleural dissemination, and/or mediastinal node involvement were excluded. Patients received two cycles of chemotherapy every 4 weeks as follows; mitomycin 8 mg/m(2) on day 1, vindesine 3 mg/m(2) on days 1 and 8, and cisplatin 80 mg/m(2) on day 1. Radiotherapy directed at the tumor and the ipsilateral supraclavicular nodes was started on day 2 of each course, at the total dose of 45 Gy in 25 fractions, with a 1-week split. Thoracotomy was undertaken 2 to 4 weeks after completion of the chemoradiotherapy. Those with unresectable disease received boost radiotherapy. RESULTS: From May 1999 to November 2002, 76 patients were enrolled, of whom 20 had T4 disease; 75 patients were fully assessable. Chemoradiotherapy was generally well tolerated. Fifty-seven patients (76%) underwent surgical resection, and pathologic complete resection was achieved in 51 patients (68%). There were 12 patients with pathologic complete response. Major postoperative morbidity, including chylothorax, empyema, pneumonitis, adult respiratory distress syndrome, and bleeding, was observed in eight patients. There were three treatment-related deaths, including two deaths owing to postsurgical complications and one death owing to sepsis during chemoradiotherapy. The disease-free and overall survival rates at 3 years were 49% and 61%, respectively; at 5 years, they were 45% and 56%, respectively. CONCLUSION: This trimodality approach is safe and effective for the treatment of patients with SSTs.

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Publishing Authors By Initials

H Kunitoh,H Kato,M Tsuboi,T Shibata,H Asamura,Y Ichonose,N Katakami,K Nagai,T Mitsudomi,A Matsumura,K Nakagawa,H Tada,N Saijo, ,H Kunitoh,H Kato,M Tsuboi,T Shibata,H Asamura,Y Ichonose,N Katakami,K Nagai,T Mitsudomi,A Matsumura,K Nakagawa,H Tada,N Saijo, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical oncology : official journal of

VOLUME: 26

Page Numbers: 644-9

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 1

MONTH: Feb

YEAR: 2008

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.

AFFILIATION: Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hkkunito@ncc.go.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806 Related Publications

• A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer.
• Advances in the treatment of non-small cell lung cancer.
• Blood Flow Visualization of Left Atrial Spontaneous Echo Contrast (SEC) Using gradient based optical flow estimation.
• Immunology: Oxysterols hold T cells in check.
• Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.
• Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
• Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.
• Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
• Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.